Cargando…

Thrombosis and Coagulopathy in COVID-19: Current Understanding and Implications for Antithrombotic Treatment in Patients Treated With Percutaneous Coronary Intervention

Coronavirus disease 2019 (COVID-19), a respiratory syndrome, is a global pandemic. Therefore, there is an urgent need to explore mechanisms implicated in the pathogenesis of the disease. Clinical and autopsy studies show a complex chain of events preceding COVID-19-related death. The disease is char...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Hangkuan, Wang, Zhijia, Sun, Haonan, Teng, Tianming, Li, Yongle, Zhou, Xin, Yang, Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847976/ https://www.ncbi.nlm.nih.gov/pubmed/33537347 http://dx.doi.org/10.3389/fcvm.2020.599334

Ejemplares similares

Antithrombotic therapy and bleeding risk in the era of aggressive lipid-lowering: current evidence, clinical implications, and future perspectives
por: Zhou, Xin, et al.
Publicado: (2023)

Coronavirus Disease 2019–Associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management
por: Ortega‐Paz, Luis, et al.
Publicado: (2021)

Antithrombotic Therapy With Ticagrelor in Atrial Fibrillation Subjects After Percutaneous Coronary Intervention
por: Lu, Wenbin, et al.
Publicado: (2021)

Editorial: Precision medicine for antithrombotic therapy in patients after percutaneous coronary interventions
por: Galli, Mattia, et al.
Publicado: (2023)

Rotational Thromboelastometry in High-Risk Patients on Dual Antithrombotic Therapy After Percutaneous Coronary Intervention
por: Hulshof, Anne-Marije, et al.
Publicado: (2021)

Antithrombotic Management for Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention or With Acute Coronary Syndrome: An Evidence-Based Update
por: Zhao, Shujuan, et al.
Publicado: (2021)

Comparative Safety and Efficacy of Eight Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
por: Liang, Bo, et al.
Publicado: (2022)

Novel strategies in antithrombotic therapy: targeting thrombosis while preserving hemostasis
por: Sim, Martha M. S., et al.
Publicado: (2023)

Evolving Antithrombotic Treatment Patterns for Patients With Nonvalvular Atrial Fibrillation and Acute Coronary Syndrome or Underwent Percutaneous Coronary Intervention in China: A Cross-Sectional Study
por: Suo, Ni, et al.
Publicado: (2022)

Clinical Valve Thrombosis and Subclinical Leaflet Thrombosis Following Transcatheter Aortic Valve Replacement: Is There a Need for a Patient-Tailored Antithrombotic Therapy?
por: Rosseel, Liesbeth, et al.
Publicado: (2019)

Update on Antithrombotic Therapy after Percutaneous Coronary Intervention
por: Saito, Yuichi, et al.
Publicado: (2019)

Graft thrombosis after coronary artery bypass surgery and current practice for prevention
por: Harik, Lamia, et al.
Publicado: (2023)

Associations of Lipoprotein(a) With Coronary Atherosclerotic Burden and All-Cause Mortality in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention
por: Xue, Yuzhou, et al.
Publicado: (2021)

Randomised controlled trial to investigate optimal antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: a study protocol of the OPTIMA-AF trial
por: Sotomi, Yohei, et al.
Publicado: (2021)

Antithrombotic Therapy for Chronic Kidney Disease Patients With Concomitant Atrial Fibrillation and Coronary Artery Disease
por: Lee, Kuo-Hua, et al.
Publicado: (2021)

Net clinical benefit of antithrombotic therapy for atrial fibrillation patients with stable coronary artery disease
por: Lee, So-Ryoung, et al.
Publicado: (2022)

Thrombosis and Coagulopathy in COVID-19
por: Gómez-Mesa, Juan Esteban, et al.
Publicado: (2021)

Patient-tailored antithrombotic therapy following percutaneous coronary intervention
por: van der Sangen, Niels M R, et al.
Publicado: (2021)

Antithrombotic management of patients with acute coronary syndrome and atrial fibrillation undergoing coronary stenting: a prospective, observational, nationwide study
por: De Luca, Leonardo, et al.
Publicado: (2020)

Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome
por: Pham, Son V, et al.
Publicado: (2010)

Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials
por: Mak, Koon-Hou
Publicado: (2012)

Coagulopathy in Beta-Thalassemia: Current Understanding and Future Perspectives
por: Cappellini, M. Domenica, et al.
Publicado: (2009)

Antithrombotic therapy in peripheral arterial disease
por: Espinola-Klein, Christine, et al.
Publicado: (2022)

COVID-19-associated coagulopathy and antithrombotic agents—lessons after 1 year
por: Leentjens, Jenneke, et al.
Publicado: (2021)

Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulation
por: Zalewski, Jarosław, et al.
Publicado: (2016)

Antithrombotic Strategy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention
por: Kwak, Soongu, et al.
Publicado: (2019)

Antithrombotic treatment in atrial fibrillation patients needing percutaneous coronary intervention
por: Huisman, M. V.
Publicado: (2021)

Chronic Total Occlusion Percutaneous Coronary Intervention in Patients With Prior Coronary Artery Bypass Graft: Current Evidence and Future Perspectives
por: Guo, Lei, et al.
Publicado: (2022)

COVID-19 coagulopathy, thrombosis, and bleeding
por: Chan, Noel C., et al.
Publicado: (2020)

Antithrombotic Therapy in Transcatheter Aortic Valve Replacement
por: Valvo, Roberto, et al.
Publicado: (2019)

Efficacy and Safety of Antithrombotic Therapy With Oral Anticoagulants in Real-World Elderly Patients With Acute Coronary Syndrome and Atrial Fibrillation
por: Wu, Yangxun, et al.
Publicado: (2022)

Robust Association Between Changes in Coronary Flow Capacity Following Percutaneous Coronary Intervention and Vessel-Oriented Outcomes and the Implication for Clinical Practice
por: Hamaya, Rikuta, et al.
Publicado: (2022)

COVID-19 and Acute Coronary Syndromes: Current Data and Future Implications
por: Cameli, Matteo, et al.
Publicado: (2021)

LEFT ATRIAL THROMBUS AND COVID-19-ASSOCIATED COAGULOPATHY
por: MA, EVA, et al.
Publicado: (2021)

Editorial: Advances in Percutaneous Coronary Intervention
por: Silverio, Angelo, et al.
Publicado: (2022)

Antithrombotic regimens for the prevention of major adverse cardiac events in chronic coronary syndrome: A systematic review and network meta-analysis
por: Marques, Gustavo Lenci, et al.
Publicado: (2023)

Antithrombotic Treatment in Lower Extremity Peripheral Arterial Disease
por: Gottsäter, Anders
Publicado: (2021)

Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention
por: Parikh, Shailja V, et al.
Publicado: (2009)

Antithrombotic Strategies in Patients with Atrial Fibrillation and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
por: De Luca, Leonardo, et al.
Publicado: (2022)

Antithrombotic Therapy After Acute Coronary Syndromes or Percutaneous Coronary Interventions in East Asian Populations
por: Kwon, Osung, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2kag3so6nivn0kgd0p20nsncr8